Virax Biolabs partners with Emory University on ViraxImmune clinical studies

Virax Biolabs (VRAX) has signed a Research Services Agreement with Emory University’s Center for the Advancement of Diagnostics for a Just Society to conduct clinical studies of ViraxImmune. These studies will focus on immune profiling in individuals with post-viral syndromes, beginning with post-acute sequelae of SARS-CoV-2, or PASC, commonly known as long COVID. Under the agreement, the Emory Laboratory for Innovative Assay Development will conduct patient recruitment, testing, and analysis to generate clinical data. This data is intended to support Virax’s planned regulatory submissions and potential future commercial rollout. This collaboration aligns with Virax’s preparations for a pre-submission meeting with the FDA in early September. The meeting will seek the FDA’s feedback on the proposed intended use and regulatory pathway for ViraxImmune in PASC. The outcome will provide formal input on the pivotal U.S. clinical trial design and inform the company’s regulatory and commercialisation strategy. ViraxImmune is a proprietary T cell testing technology designed to evaluate a patient’s immune response profile.